Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Santora

Showing results (41-50 of 63) with videos related to

Pageof 7
Sort By:
Journal of Bone and Mineral Metabolism|September 1, 2005
Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized studyShinji Uchida, Tadaaki Taniguchi, Takafumi Shimizu, et al.
Radiology|July 1, 1983
Work in progress: abnormal parathyroid glands. Comparison of nonselective arterial digital arteriography, selective parathyroid arteriography, and venous digital arteriography as methods of detectionA G Krudy, J L Doppman, D L Miller, et al.
Annals of Surgery|October 1, 1984
Intraoperative urinary cyclic adenosine monophosphate as a guide to successful reoperative parathyroidectomyJ A Norton, M F Brennan, A W Saxe, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|December 10, 2002
Prediction of fracture risk in postmenopausal white women with peripheral bone densitometry: evidence from the National Osteoporosis Risk AssessmentPaul D Miller, Ethel S Siris, Elizabeth Barrett-Connor, et al.
The Journal of Clinical Endocrinology and Metabolism|September 22, 2000
Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study GroupR P Tonino, P J Meunier, R Emkey, et al.
Menopause (New York, N.Y.)|November 17, 2004
Changes in bone density and turnover after alendronate or estrogen withdrawalRichard D Wasnich, Yu Z Bagger, David J Hosking, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|July 3, 2004
Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extensionKristine E Ensrud, Elizabeth L Barrett-Connor, Ann Schwartz, et al.
The New England Journal of Medicine|March 19, 2004
Ten years' experience with alendronate for osteoporosis in postmenopausal womenHenry G Bone, David Hosking, Jean-Pierre Devogelaer, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|July 22, 2017
Evaluating Atypical Features of Femur Fractures: How Change in Radiological Criteria Influenced Incidence and Demography of Atypical Femur Fractures in a Community SettingErin S LeBlanc, A Gabriela Rosales, Dennis M Black, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|February 28, 2019
Radiological criteria for atypical features of femur fractures: what we can learn when applied in a clinical study settingE S LeBlanc, A G Rosales, H K Genant, et al.
Pageof 7

Showing results (41-50 of 63) with videos related to

Sort By:
Pageof 7
Journal of Bone and Mineral Metabolism|September 1, 2005
Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized studyShinji Uchida, Tadaaki Taniguchi, Takafumi Shimizu, et al.
Radiology|July 1, 1983
Work in progress: abnormal parathyroid glands. Comparison of nonselective arterial digital arteriography, selective parathyroid arteriography, and venous digital arteriography as methods of detectionA G Krudy, J L Doppman, D L Miller, et al.
Annals of Surgery|October 1, 1984
Intraoperative urinary cyclic adenosine monophosphate as a guide to successful reoperative parathyroidectomyJ A Norton, M F Brennan, A W Saxe, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|December 10, 2002
Prediction of fracture risk in postmenopausal white women with peripheral bone densitometry: evidence from the National Osteoporosis Risk AssessmentPaul D Miller, Ethel S Siris, Elizabeth Barrett-Connor, et al.
The Journal of Clinical Endocrinology and Metabolism|September 22, 2000
Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study GroupR P Tonino, P J Meunier, R Emkey, et al.
Menopause (New York, N.Y.)|November 17, 2004
Changes in bone density and turnover after alendronate or estrogen withdrawalRichard D Wasnich, Yu Z Bagger, David J Hosking, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|July 3, 2004
Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extensionKristine E Ensrud, Elizabeth L Barrett-Connor, Ann Schwartz, et al.
The New England Journal of Medicine|March 19, 2004
Ten years' experience with alendronate for osteoporosis in postmenopausal womenHenry G Bone, David Hosking, Jean-Pierre Devogelaer, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|July 22, 2017
Evaluating Atypical Features of Femur Fractures: How Change in Radiological Criteria Influenced Incidence and Demography of Atypical Femur Fractures in a Community SettingErin S LeBlanc, A Gabriela Rosales, Dennis M Black, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|February 28, 2019
Radiological criteria for atypical features of femur fractures: what we can learn when applied in a clinical study settingE S LeBlanc, A G Rosales, H K Genant, et al.
Pageof 7